Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Heitmeier

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Thrombosis and Haemostasis : JTH|November 16, 2021
Variation of platelet function in clinical phenotypes of acute venous thromboembolism - Results from the GMP-VTE projectMarina Panova-Noeva, Bianca Wagner, Markus Nagler, et al.
Blood Advances|January 15, 2020
Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factorSteven P Grover, Clare M Schmedes, Alyson C Auriemma, et al.
Ebiomedicine|September 13, 2020
Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observation studiesMarina Panova-Noeva, Bianca Wagner, Markus Nagler, et al.
Journal of Medicinal Chemistry|September 5, 2023
Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic DisordersSusanne Roehrig, Jens Ackerstaff, Eloísa Jiménez Núñez, et al.
Journal of Medicinal Chemistry|November 14, 2024
Discovery and Preclinical Characterization of Fulacimstat (BAY 1142524), a Potent and Selective Chymase Inhibitor As a New Profibrinolytic Approach for Safe Thrombus ResolutionChantal Fürstner, Jens Ackerstaff, Heinrich Meier, et al.
Blood Advances|March 29, 2018
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarctionOliver Borst, Patrick Münzer, Nada Alnaggar, et al.
Blood Advances|July 26, 2021
A targeted proteomics investigation of the obesity paradox in venous thromboembolismVincent Ten Cate, Thomas Koeck, Jürgen Prochaska, et al.
Translational Psychiatry|May 18, 2024
The circulating proteome and brain health: Mendelian randomisation and cross-sectional analysesRosie M Walker, Michael Chong, Nicolas Perrot, et al.
Journal of Medicinal Chemistry|June 11, 2025
Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced CoagulopathyHartmut Beck, Stefanie Mesch, Stefanie Zimmermann, et al.
Thrombosis Research|May 18, 2023
Unsupervised clustering of venous thromboembolism patients by clinical features at presentation identifies novel endotypes that improve prognostic stratificationAlejandro Pallares Robles, Vincent Ten Cate, Michael Lenz, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Thrombosis and Haemostasis : JTH|November 16, 2021
Variation of platelet function in clinical phenotypes of acute venous thromboembolism - Results from the GMP-VTE projectMarina Panova-Noeva, Bianca Wagner, Markus Nagler, et al.
Blood Advances|January 15, 2020
Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factorSteven P Grover, Clare M Schmedes, Alyson C Auriemma, et al.
Ebiomedicine|September 13, 2020
Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observation studiesMarina Panova-Noeva, Bianca Wagner, Markus Nagler, et al.
Journal of Medicinal Chemistry|September 5, 2023
Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic DisordersSusanne Roehrig, Jens Ackerstaff, Eloísa Jiménez Núñez, et al.
Journal of Medicinal Chemistry|November 14, 2024
Discovery and Preclinical Characterization of Fulacimstat (BAY 1142524), a Potent and Selective Chymase Inhibitor As a New Profibrinolytic Approach for Safe Thrombus ResolutionChantal Fürstner, Jens Ackerstaff, Heinrich Meier, et al.
Blood Advances|March 29, 2018
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarctionOliver Borst, Patrick Münzer, Nada Alnaggar, et al.
Blood Advances|July 26, 2021
A targeted proteomics investigation of the obesity paradox in venous thromboembolismVincent Ten Cate, Thomas Koeck, Jürgen Prochaska, et al.
Translational Psychiatry|May 18, 2024
The circulating proteome and brain health: Mendelian randomisation and cross-sectional analysesRosie M Walker, Michael Chong, Nicolas Perrot, et al.
Journal of Medicinal Chemistry|June 11, 2025
Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced CoagulopathyHartmut Beck, Stefanie Mesch, Stefanie Zimmermann, et al.
Thrombosis Research|May 18, 2023
Unsupervised clustering of venous thromboembolism patients by clinical features at presentation identifies novel endotypes that improve prognostic stratificationAlejandro Pallares Robles, Vincent Ten Cate, Michael Lenz, et al.
Pageof 5